Tobacco cessation for nonpregnant adults: USPSTF guidance requires clinicians to do what?

• A. Clinicians should ask all adults about tobacco use, advise them to stop, and provide behavioral interventions and FDA-approved pharmacotherapy.
• B. Pharmacotherapy alone without behavioral interventions is recommended.
• C. No counseling is recommended.
• D. Clinicians should only advise to stop if the patient has a smoking-related illness.

Answer: (A)

The main idea here is that the USPSTF promotes a comprehensive, universal approach to tobacco cessation in nonpregnant adults: clinicians should screen every adult for tobacco use, give clear advice to quit, and offer or refer for evidence-based cessation treatments, which include both behavioral interventions (counseling) and FDA-approved pharmacotherapy.

This combination is supported by evidence showing that counseling plus pharmacotherapy increases quit rates more than either component alone or no intervention. So the option that asks all adults about tobacco use, advises them to quit, and provides behavioral interventions alongside FDA-approved pharmacotherapy best reflects the USPSTF guidance.

The other choices fall short because they omit essential components. Pharmacotherapy alone lacks the behavioral support that boosts success; no counseling ignores proven benefits of counseling; and advising only if a patient has a smoking-related illness misses the universal screening and offer-and-support approach the USPSTF endorses.